lobbying_activities: 3504869

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
3504869	fe166397-50a6-4045-bc15-ecb5c3b7bf3f	Q4	BUCHANAN INGERSOLL & ROONEY PC	55291	GENERIC ANIMAL DRUG ALLIANCE	2025	fourth_quarter	ANI	Strategy development and implementation of federal government relations initiatives relating to generic animal drug industry. H.R. 1683, the Generic Animal Drug Advancement Act, all provisions; H.R. 1418, the Animal Drug User Fee Amendments of 2023, all provisions	Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE			0	0	2026-01-20T12:07:25-05:00